Researchers report improved progression-free survival for lutathera over octreotide

(H. Lee Moffitt Cancer Center & Research Institute) Moffitt Cancer Center will present results of the phase 3 NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, 2016 during the American Society of Clinical Oncology Annual Meeting in Chicago.